{
    "cancer_info": {
        "cancer_name": "Cutaneous Melanoma"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Excisional biopsy",
            "Punch/saucerization biopsy",
            "Fine needle aspiration (FNA) biopsy",
            "Core biopsy",
            "Lymphoscintigraphy",
            "Sentinel lymph node biopsy (SLNB)",
            "CT scan (chest/abdomen/pelvis)",
            "PET-CT scan",
            "Brain MRI",
            "Ultrasound (nodal basins)",
            "Pelvic CT (for inguinal involvement)",
            "BRAF V600 mutation testing",
            "KIT mutation testing",
            "NRAS mutation testing",
            "NTRK/ROS1 fusion testing",
            "PD-L1 IHC testing",
            "Tumor Mutational Burden (TMB) via NGS",
            "LDH serum test",
            "Pathology assessment (Breslow thickness, ulceration, mitotic rate, margins)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage 0 (In situ)",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "All patients",
                    "plan_name": "Wide excision",
                    "plan_details": "0.5–1 cm margins",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IA-IB",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "T1a (≤0.8mm, no ulceration)",
                    "plan_name": "Wide excision",
                    "plan_details": "1 cm margins; SLNB not routinely recommended",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "T1b (>0.8mm ulcerated)",
                    "plan_name": "Wide excision + SLNB",
                    "plan_details": "1 cm margins; consider SLNB if adverse features present",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IIB-IIC",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "Resected disease",
                    "plan_name": "Pembrolizumab or Nivolumab",
                    "plan_details": "Anti-PD-1 immunotherapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Surgical management",
                    "patient_subgroup": "Primary tumor",
                    "plan_name": "Wide excision",
                    "plan_details": "2 cm margins for tumors >2mm",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage III (Resectable)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "Neoadjuvant therapy",
                    "patient_subgroup": "Clinically positive nodes",
                    "plan_name": "Nivolumab + Ipilimumab",
                    "plan_details": "2 doses pre-surgery",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "Post-resection",
                    "plan_name": "Pembrolizumab or Nivolumab",
                    "plan_details": "Anti-PD-1 immunotherapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "BRAF V600+",
                    "plan_name": "Dabrafenib + Trametinib",
                    "plan_details": "BRAF/MEK inhibitor combination",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage III (Unresectable in-transit)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "Local therapy",
                    "patient_subgroup": "Injectable lesions",
                    "plan_name": "T-VEC",
                    "plan_details": "Intralesional oncolytic virus",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "Regional therapy",
                    "patient_subgroup": "Extremity-confined disease",
                    "plan_name": "Isolated Limb Perfusion/Infusion",
                    "plan_details": "Melphalan ± actinomycin D/TNF-α",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (Metastatic)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "BRAF Wild-Type",
                    "plan_name": "Anti-PD-1 monotherapy",
                    "plan_details": "Pembrolizumab 200mg Q3W or Nivolumab 480mg Q4W",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "BRAF V600+",
                    "plan_name": "BRAF/MEK inhibitors",
                    "plan_details": "Dabrafenib 150mg BID + Trametinib 2mg QD",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "High tumor burden",
                    "plan_name": "Nivolumab + Ipilimumab",
                    "plan_details": "Combination immunotherapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line therapy",
                    "patient_subgroup": "PD-1 refractory",
                    "plan_name": "Lifileucel (TIL therapy)",
                    "plan_details": "Tumor-infiltrating lymphocyte therapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "Brain metastases",
                    "patient_subgroup": "All patients",
                    "plan_name": "Stereotactic radiosurgery (SRS)",
                    "plan_details": "15–24 Gy/1 fraction",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "BRAF V600: Predicts response to BRAF/MEK inhibitors; KIT mutations: Predict response to KIT inhibitors in acral/mucosal subtypes; LDH: Prognostic marker in stage IV (elevated levels correlate with poor survival); Microsatellitosis: Defines ≥ stage IIIB and high recurrence risk; PD-L1: Emerging biomarker for anti-PD-1 response (not definitive); TMB: Correlates with immunotherapy response; NRAS mutations: Associated with poor prognosis"
    },
    "guideline_id": "（2025.V2）NCCN临床实践指南：皮肤黑色素瘤.txt"
}